A monthly audio round-up detailing the contents of the latest issue of DTB. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast...
https://dtbbmj.podbean.com
Tamiflu - the wrong message?
The widespread use of oseltamivir (Tamiflu) has been a key strategy in tackling the H1N1 ‘swine flu’ pandemic in the UK. However, there have been growing concerns about the communication of this approach and rationale behind the policy itself. In this podcast Dr Ike Iheanacho, DTB editor, discusses the policy with two members of the DTB editorial board, Dr Paul Caldwell, a general practitioner and Dr Mahdad Noursadeghi, an infectious diseases consultant. This is an extension of our September 2009 Editorial, Tamiflu − the wrong message? DTB 2009; 47: 97.